Table 3.
HRV Index | |||||||
---|---|---|---|---|---|---|---|
Gender | Log-HF (ms2) β (SE) |
Log LF (ms2) β (SE) |
LF/HF ratio β (SE) |
SDNN (ms) β (SE) |
RMSSD (ms) β (SE) |
HR (bpm) β (SE) |
|
cMetS | M | −0.13(0.03)** | −0.08(0.01)** | 0.15(0.03)** | −3.38(0.66)** | −2.74(0.97)** | 1.85(0.35)** |
F | −0.05(0.03) | −0.05(0.02)** | 0.01(0.03) | −0.35(0.74) | −0.32(1.08) | 1.02(0.38)** | |
WC | M | −0.13(0.03)** | −0.08(0.01)** | 0.12(0.03)** | −3.28(0.68)** | −2.60(0.99)** | 1.76(0.36)** |
F | 0.02(0.04) | −0.03(0.02) | −0.10(0.04)** | 0.12(0.83) | 1.97(1.21) | 0.11(0.43) | |
MAP | M | −0.06(0.03)* | −0.03(0.02)* | 0.07(0.03)* | −1.86(0.72)** | −0.67(1.04) | 0.88(0.38)* |
F | −0.11(0.03)** | −0.08(0.02)** | 0.05(0.03) | −2.43(0.75)** | −3.02(1.09)** | 1.74(0.38)** | |
Log HOMA-IR | M | −0.13(0.03)** | −0.09(0.02)** | 0.11(0.03)** | −3.78(0.73)** | −3.35(1.06)** | 2.20(0.38)** |
F | 0.01(0.03) | −0.02(0.02) | −0.07(0.03)* | 0.83(0.72) | 0.74(1.05) | 0.46(0.37) | |
TG | M | −0.10(0.03)** | −0.08(0.01)** | 0.09(0.03)** | −3.43(0.63)** | −2.22(0.93)* | 2.06(0.33)** |
F | −0.18(0.03)** | −0.11(0.02)** | 0.15(0.03)** | −3.48(0.75)** | –3.47(1.15)** | 1.81(0.41)** | |
HDL | M | –0.07(0.04) | –0.002(0.02) | 0.15(0.04)** | 0.73(0.87) | –1.58(1.27) | –0.33(0.47) |
F | 0.09(0.03)** | 0.07(0.02)** | –0.05(0.03) | 3.74(0.69)** | 2.98(1.00)** | –0.61(0.36) |
Abbreviations: BPM, beats per minute; cMetS, continuous metabolic syndrome score; F, female; HDL, high-density lipoprotein; HF, high frequency power; HOMA-IR, homeostasis model assessment of insulin resistance; HRV, heart rate variability; LF, low frequency power; Log, logarithm; M, male; MAP, mean arterial pressure; RMSSD, square root of the mean of the sum of the squares of differences between adjacent RR intervals; SDNN, standard deviation of all RR intervals; TG, triglycerides; WC, waist circumference.
The model was adjusted for age, and race.
* and **, P < 0.05; and P < 0.01, respectively.